<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296192</url>
  </required_header>
  <id_info>
    <org_study_id>SP0873</org_study_id>
    <secondary_id>EudraCT: 2005-004290-19</secondary_id>
    <nct_id>NCT00296192</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Parallel-Group, Proof of Concept Trial to Assess the Tolerability, Safety, and Efficacy of Rotigotine Nasal Spray for the Acute Treatment of &quot;OFF&quot; Symptoms in Subjects With Advanced-Stage, Idiopathic Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM
      952) in a single dose application scheme.

      Subjects will undergo a 2 - 28 days screening period in which eligibility criteria will be
      checked. Subjects will then be hospitalized for one night. In the morning of the next day,
      subjects will be randomly assigned either to rotigotine or placebo nasal spray and will then
      receive a single dose of trial medication. Safety assessments after application include
      adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and
      laboratory checks. Efficacy will be assessed by application of motor examination scores.

      The first subject is planned to be enrolled in February 2006. The last subject is planned to
      be enrolled in May 2006. Last subject out is expected for August 2006.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM
      952)in a single dose application scheme. Subjects will undergo a 2-28 days screening period
      in which eligibility criteria will be checked. Subjects will then be hospitalized for one
      night. In the morning of the next day, subjects will be randomly assigned either to
      rotigotine or placebo nasal spray and will then receive a single dose of trial medication.
      Safety assessments after application include adverse events, 12-lead electrocardiograms,
      blood pressure and heart rate assessments, and laboratory checks. Efficacy will be assessed
      by application of motor examination scores.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Complete the Trial</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 24 Minutes Post-dose in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination</measure>
    <time_frame>Baseline, and 24 minutes post-dose</time_frame>
    <description>The Unified Parkinson's Disease Rating Scale (UPDRS) is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Examination. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 24 minute value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 34 Minutes Post-dose in Tapping Rate (Taps/Min)</measure>
    <time_frame>Baseline and 34 minutes post-dose</time_frame>
    <description>One-minute tapping rate will be calculated as the number of times a subject could tap on two 4 x 4 cm marks placed on a board 30 cm apart during 1 minute (30 cm measured from the inner border of the two boxes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Success Rate&quot; (Percentage of Subjects Achieving &quot;Off&quot; Reversals)</measure>
    <time_frame>Up to 6 hours post-dose</time_frame>
    <description>Subjects reversing from &quot;off&quot; to &quot;on&quot; following initiation of treatment. &quot;On&quot; and &quot;off&quot; state refer to periods where Parkinson's disease symptoms are not present (&quot;on&quot;) and periods where symptoms are present (&quot;off&quot;); the &quot;on&quot;/&quot;off&quot; determination at each assessment timepoint was made by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of First &quot;Off&quot; Reversal</measure>
    <time_frame>Up to 6 hours post-dose</time_frame>
    <description>Number of minutes to first reversal of symptoms from &quot;off&quot; to &quot;on&quot;. Estimated via Kaplan-Meier estimation method. &quot;On&quot; and &quot;off&quot; state refer to periods where Parkinson's disease symptoms are not present (&quot;on&quot;) and periods where symptoms are present (&quot;off&quot;); the &quot;on&quot;/&quot;off&quot; determination at each assessment timepoint was made by the investigator.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray 1 - 4 puffs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotigotine 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotigotine 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotigotine 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotigotine 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine nasal spray</intervention_name>
    <description>Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries</description>
    <arm_group_label>Rotigotine 1</arm_group_label>
    <arm_group_label>Rotigotine 2</arm_group_label>
    <arm_group_label>Rotigotine 3</arm_group_label>
    <arm_group_label>Rotigotine 4</arm_group_label>
    <other_name>Neupro</other_name>
    <other_name>SPM 952</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo nasal spray 1, 2 3, and 4 puffs</description>
    <arm_group_label>Placebo 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with idiopathic Parkinson's disease for at least 3 years in
             duration

          -  At least 30 years of age

        Exclusion Criteria:

          -  Patients with atypical Parkinson's or clinically relevant concomitant diseases or
             medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2006</study_first_submitted>
  <study_first_submitted_qc>February 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <results_first_submitted>July 30, 2009</results_first_submitted>
  <results_first_submitted_qc>January 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2010</results_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotigotine</keyword>
  <keyword>Rotigotine nasal spray</keyword>
  <keyword>Efficacy, safety and tolerability</keyword>
  <keyword>Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants flow shows all subjects randomized. Safety analyses are based on actual treatment received; 4 subjects randomized to placebo were mistreated (1 subject each in the rotigotine 1 puff, rotigotine 2 puffs, rotigotine 3 puffs, and rotigotine 4 puffs treatment arms).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo 1-4 Puffs</title>
          <description>Placebo nasal spray 1 - 4 puffs</description>
        </group>
        <group group_id="P2">
          <title>Rotigotine 1 Puff</title>
          <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
        </group>
        <group group_id="P3">
          <title>Rotigotine 2 Puffs</title>
          <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
        </group>
        <group group_id="P4">
          <title>Rotigotine 3 Puffs</title>
          <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
        </group>
        <group group_id="P5">
          <title>Rotigotine 4 Puffs</title>
          <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo 1-4 Puffs</title>
          <description>Placebo nasal spray 1 - 4 puffs</description>
        </group>
        <group group_id="B2">
          <title>Rotigotine 1 Puff</title>
          <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
        </group>
        <group group_id="B3">
          <title>Rotigotine 2 Puffs</title>
          <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
        </group>
        <group group_id="B4">
          <title>Rotigotine 3 Puffs</title>
          <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
        </group>
        <group group_id="B5">
          <title>Rotigotine 4 Puffs</title>
          <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="6.94"/>
                    <measurement group_id="B2" value="67.1" spread="7.54"/>
                    <measurement group_id="B3" value="66.8" spread="9.67"/>
                    <measurement group_id="B4" value="63.9" spread="8.28"/>
                    <measurement group_id="B5" value="60.5" spread="8.04"/>
                    <measurement group_id="B6" value="64.4" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Complete the Trial</title>
        <time_frame>15 days</time_frame>
        <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 1-4 Puffs</title>
            <description>Placebo nasal spray 1 - 4 puffs</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 1 Puff</title>
            <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 2 Puffs</title>
            <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
          </group>
          <group group_id="O4">
            <title>Rotigotine 3 Puffs</title>
            <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
          </group>
          <group group_id="O5">
            <title>Rotigotine 4 Puffs</title>
            <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Complete the Trial</title>
          <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 24 Minutes Post-dose in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination</title>
        <description>The Unified Parkinson's Disease Rating Scale (UPDRS) is a scale for the assessment of function in Parkinson’s disease. UPDRS Part III measures Motor Examination. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 24 minute value minus baseline value.</description>
        <time_frame>Baseline, and 24 minutes post-dose</time_frame>
        <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement. Missing values at 24 minutes post-dose timepoint were not imputed; number of observations at 24 minutes post-dose timepoint may be less than that for baseline timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 1-4 Puffs</title>
            <description>Placebo nasal spray 1 - 4 puffs</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 1 Puff</title>
            <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 2 Puffs</title>
            <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
          </group>
          <group group_id="O4">
            <title>Rotigotine 3 Puffs</title>
            <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
          </group>
          <group group_id="O5">
            <title>Rotigotine 4 Puffs</title>
            <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 24 Minutes Post-dose in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination</title>
          <description>The Unified Parkinson's Disease Rating Scale (UPDRS) is a scale for the assessment of function in Parkinson’s disease. UPDRS Part III measures Motor Examination. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 24 minute value minus baseline value.</description>
          <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement. Missing values at 24 minutes post-dose timepoint were not imputed; number of observations at 24 minutes post-dose timepoint may be less than that for baseline timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="7.77"/>
                    <measurement group_id="O2" value="37.2" spread="10.68"/>
                    <measurement group_id="O3" value="39.5" spread="12.94"/>
                    <measurement group_id="O4" value="36.2" spread="7.60"/>
                    <measurement group_id="O5" value="37.6" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="12.44"/>
                    <measurement group_id="O2" value="30.0" spread="11.35"/>
                    <measurement group_id="O3" value="29.2" spread="13.53"/>
                    <measurement group_id="O4" value="29.1" spread="8.51"/>
                    <measurement group_id="O5" value="26.4" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 24 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="7.8"/>
                    <measurement group_id="O2" value="-7.2" spread="10.32"/>
                    <measurement group_id="O3" value="-10.3" spread="6.17"/>
                    <measurement group_id="O4" value="-7.1" spread="6.47"/>
                    <measurement group_id="O5" value="-11.6" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance modeling change from baseline at 24 minutes post-dose in UPDRS Part III, controlling for treatment group and baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance modeling change from baseline at 24 minutes post-dose in UPDRS Part III, controlling for treatment group and baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance modeling change from baseline at 24 minutes post-dose in UPDRS Part III, controlling for treatment group and baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance modeling change from baseline at 24 minutes post-dose in UPDRS Part III, controlling for treatment group and baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 34 Minutes Post-dose in Tapping Rate (Taps/Min)</title>
        <description>One-minute tapping rate will be calculated as the number of times a subject could tap on two 4 x 4 cm marks placed on a board 30 cm apart during 1 minute (30 cm measured from the inner border of the two boxes).</description>
        <time_frame>Baseline and 34 minutes post-dose</time_frame>
        <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement. Missing values at 34 minutes post-dose timepoint were not imputed; number of observations at 34 minutes post-dose timepoint may be less than that for baseline timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 1-4 Puffs</title>
            <description>Placebo nasal spray 1 - 4 puffs</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 1 Puff</title>
            <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 2 Puffs</title>
            <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
          </group>
          <group group_id="O4">
            <title>Rotigotine 3 Puffs</title>
            <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
          </group>
          <group group_id="O5">
            <title>Rotigotine 4 Puffs</title>
            <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 34 Minutes Post-dose in Tapping Rate (Taps/Min)</title>
          <description>One-minute tapping rate will be calculated as the number of times a subject could tap on two 4 x 4 cm marks placed on a board 30 cm apart during 1 minute (30 cm measured from the inner border of the two boxes).</description>
          <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement. Missing values at 34 minutes post-dose timepoint were not imputed; number of observations at 34 minutes post-dose timepoint may be less than that for baseline timepoint.</population>
          <units>taps per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.7" spread="47.08"/>
                    <measurement group_id="O2" value="109.8" spread="28.94"/>
                    <measurement group_id="O3" value="127.2" spread="44.33"/>
                    <measurement group_id="O4" value="115.9" spread="41.05"/>
                    <measurement group_id="O5" value="118.3" spread="40.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.2" spread="50.92"/>
                    <measurement group_id="O2" value="131.0" spread="30.01"/>
                    <measurement group_id="O3" value="138.7" spread="44.42"/>
                    <measurement group_id="O4" value="142.9" spread="51.20"/>
                    <measurement group_id="O5" value="144.4" spread="57.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 34 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="27.83"/>
                    <measurement group_id="O2" value="21.2" spread="26.69"/>
                    <measurement group_id="O3" value="11.5" spread="11.27"/>
                    <measurement group_id="O4" value="27.1" spread="25.25"/>
                    <measurement group_id="O5" value="22.9" spread="27.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance modeling change from baseline to 34 minutes post-dose in tapping rate, controlling for treatment group and baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.7</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance modeling change from baseline to 34 minutes post-dose in tapping rate, controlling for treatment group and baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-16.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-34.0</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance modeling change from baseline to 34 minutes post-dose in tapping rate, controlling for treatment group and baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.2</ci_lower_limit>
            <ci_upper_limit>15.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance modeling change from baseline to 34 minutes post-dose in tapping rate, controlling for treatment group and baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-23.3</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>&quot;Success Rate&quot; (Percentage of Subjects Achieving &quot;Off&quot; Reversals)</title>
        <description>Subjects reversing from &quot;off&quot; to &quot;on&quot; following initiation of treatment. &quot;On&quot; and &quot;off&quot; state refer to periods where Parkinson's disease symptoms are not present (&quot;on&quot;) and periods where symptoms are present (&quot;off&quot;); the &quot;on&quot;/&quot;off&quot; determination at each assessment timepoint was made by the investigator.</description>
        <time_frame>Up to 6 hours post-dose</time_frame>
        <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 1-4 Puffs</title>
            <description>Placebo nasal spray 1 - 4 puffs</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 1 Puff</title>
            <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 2 Puffs</title>
            <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
          </group>
          <group group_id="O4">
            <title>Rotigotine 3 Puffs</title>
            <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
          </group>
          <group group_id="O5">
            <title>Rotigotine 4 Puffs</title>
            <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
          </group>
        </group_list>
        <measure>
          <title>&quot;Success Rate&quot; (Percentage of Subjects Achieving &quot;Off&quot; Reversals)</title>
          <description>Subjects reversing from &quot;off&quot; to &quot;on&quot; following initiation of treatment. &quot;On&quot; and &quot;off&quot; state refer to periods where Parkinson's disease symptoms are not present (&quot;on&quot;) and periods where symptoms are present (&quot;off&quot;); the &quot;on&quot;/&quot;off&quot; determination at each assessment timepoint was made by the investigator.</description>
          <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reversed from &quot;off&quot; to &quot;on&quot; (success)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="75.0"/>
                    <measurement group_id="O4" value="70.6"/>
                    <measurement group_id="O5" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not reverse from &quot;off&quot; to &quot;on&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="29.4"/>
                    <measurement group_id="O5" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval in difference in success rate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in proportions</param_type>
            <param_value>-20.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-53.3</ci_lower_limit>
            <ci_upper_limit>12.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval in difference in success rate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in proportions</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.9</ci_lower_limit>
            <ci_upper_limit>34.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval in difference in success rate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-30.6</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>95% confidence interval in difference in success rate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in proportions</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.9</ci_lower_limit>
            <ci_upper_limit>34.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of First &quot;Off&quot; Reversal</title>
        <description>Number of minutes to first reversal of symptoms from &quot;off&quot; to &quot;on&quot;. Estimated via Kaplan-Meier estimation method. &quot;On&quot; and &quot;off&quot; state refer to periods where Parkinson's disease symptoms are not present (&quot;on&quot;) and periods where symptoms are present (&quot;off&quot;); the &quot;on&quot;/&quot;off&quot; determination at each assessment timepoint was made by the investigator.</description>
        <time_frame>Up to 6 hours post-dose</time_frame>
        <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo 1-4 Puffs</title>
            <description>Placebo nasal spray 1 - 4 puffs</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 1 Puff</title>
            <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 2 Puffs</title>
            <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
          </group>
          <group group_id="O4">
            <title>Rotigotine 3 Puffs</title>
            <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
          </group>
          <group group_id="O5">
            <title>Rotigotine 4 Puffs</title>
            <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
          </group>
        </group_list>
        <measure>
          <title>Time of First &quot;Off&quot; Reversal</title>
          <description>Number of minutes to first reversal of symptoms from &quot;off&quot; to &quot;on&quot;. Estimated via Kaplan-Meier estimation method. &quot;On&quot; and &quot;off&quot; state refer to periods where Parkinson's disease symptoms are not present (&quot;on&quot;) and periods where symptoms are present (&quot;off&quot;); the &quot;on&quot;/&quot;off&quot; determination at each assessment timepoint was made by the investigator.</description>
          <population>Full Analysis Set: Subjects receiving at least one delivery of trial medication and with at least one post-baseline efficacy measurement.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="24" upper_limit="65"/>
                    <measurement group_id="O2" value="60" lower_limit="40" upper_limit="60"/>
                    <measurement group_id="O3" value="51" lower_limit="22" upper_limit="84"/>
                    <measurement group_id="O4" value="50" lower_limit="35" upper_limit="70"/>
                    <measurement group_id="O5" value="59" lower_limit="35" upper_limit="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety analyses are based on actual treatment received; 4 subjects randomized to placebo were mistreated (1 subject each in the rotigotine 1 puff, rotigotine 2 puffs, rotigotine 3 puffs, and rotigotine 4 puffs treatment arms).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo 1-4 Puffs</title>
          <description>Placebo nasal spray 1 - 4 puffs</description>
        </group>
        <group group_id="E2">
          <title>Rotigotine 1 Puff</title>
          <description>Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)</description>
        </group>
        <group group_id="E3">
          <title>Rotigotine 2 Puffs</title>
          <description>Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)</description>
        </group>
        <group group_id="E4">
          <title>Rotigotine 3 Puffs</title>
          <description>Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)</description>
        </group>
        <group group_id="E5">
          <title>Rotigotine 4 Puffs</title>
          <description>Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Application site paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Difficulty in walking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>White blood cells urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>White blood cells urine postitive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sleep attacks</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 days but &lt;= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB Pharma</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

